Literature DB >> 33462181

The BET family in immunity and disease.

Nian Wang1, Runliu Wu1, Daolin Tang2, Rui Kang3.   

Abstract

Innate immunity serves as the rapid and first-line defense against invading pathogens, and this process can be regulated at various levels, including epigenetic mechanisms. The bromodomain and extraterminal domain (BET) family of proteins consists of four conserved mammalian members (BRD2, BRD3, BRD4, and BRDT) that regulate the expression of many immunity-associated genes and pathways. In particular, in response to infection and sterile inflammation, abnormally expressed or dysfunctional BETs are involved in the activation of pattern recognition receptor (e.g., TLR, NLR, and CGAS) pathways, thereby linking chromatin machinery to innate immunity under disease or pathological conditions. Mechanistically, the BET family controls the transcription of a wide range of proinflammatory and immunoregulatory genes by recognizing acetylated histones (mainly H3 and H4) and recruiting transcription factors (e.g., RELA) and transcription elongation complex (e.g., P-TEFb) to the chromatin, thereby promoting the phosphorylation of RNA polymerase II and subsequent transcription initiation and elongation. This review covers the accumulating data about the roles of the BET family in innate immunity, and discusses the attractive prospect of manipulating the BET family as a new treatment for disease.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33462181      PMCID: PMC7813845          DOI: 10.1038/s41392-020-00384-4

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  198 in total

Review 1.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

2.  Molecular basis for the specific recognition of the metazoan cyclic GMP-AMP by the innate immune adaptor protein STING.

Authors:  Heping Shi; Jiaxi Wu; Zhijian J Chen; Chuo Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

3.  Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA.

Authors:  Z Zou; B Huang; X Wu; H Zhang; J Qi; J Bradner; S Nair; L-F Chen
Journal:  Oncogene       Date:  2013-05-20       Impact factor: 9.867

4.  Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis.

Authors:  Fei Jiang; Qinghua Hu; Zhimin Zhang; Hongmei Li; Huili Li; Dewei Zhang; Hanwen Li; Yu Ma; Jingjing Xu; Haifang Chen; Yong Cui; Yanle Zhi; Yanmin Zhang; Junyu Xu; Jiapeng Zhu; Tao Lu; Yadong Chen
Journal:  J Med Chem       Date:  2019-12-13       Impact factor: 7.446

5.  Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762.

Authors:  Di Zhang; Ana S Leal; Sarah Carapellucci; Kayla Zydeck; Michael B Sporn; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2017-12-15

6.  Targeting bromodomain-containing proteins to prevent spontaneous preterm birth.

Authors:  Ratana Lim; Caitlyn Nguyen-Ngo; Martha Lappas
Journal:  Clin Sci (Lond)       Date:  2019-12-12       Impact factor: 6.124

7.  A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.

Authors:  Tingting Wang; Dangge Wang; Haijun Yu; Bing Feng; Fangyuan Zhou; Hanwu Zhang; Lei Zhou; Shi Jiao; Yaping Li
Journal:  Nat Commun       Date:  2018-04-18       Impact factor: 14.919

Review 8.  The emerging role of epigenetic therapeutics in immuno-oncology.

Authors:  Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675

9.  BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.

Authors:  Jude T Deeney; Anna C Belkina; Orian S Shirihai; Barbara E Corkey; Gerald V Denis
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

10.  Selective BET bromodomain inhibition as an antifungal therapeutic strategy.

Authors:  Flore Mietton; Elena Ferri; Morgane Champleboux; Ninon Zala; Danièle Maubon; Yingsheng Zhou; Mike Harbut; Didier Spittler; Cécile Garnaud; Marie Courçon; Murielle Chauvel; Christophe d'Enfert; Boris A Kashemirov; Mitchell Hull; Muriel Cornet; Charles E McKenna; Jérôme Govin; Carlo Petosa
Journal:  Nat Commun       Date:  2017-05-18       Impact factor: 14.919

View more
  35 in total

Review 1.  The role of protein acetylation in carcinogenesis and targeted drug discovery.

Authors:  Jingru Yang; Cong Song; Xianquan Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-12       Impact factor: 6.055

2.  A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization.

Authors:  Tingting Yang; Yuzhu Hu; Junming Miao; Jing Chen; Jiagang Liu; Yongzhong Cheng; Xiang Gao
Journal:  Acta Pharm Sin B       Date:  2022-02-16       Impact factor: 14.903

3.  KSHV episome tethering sites on host chromosomes and regulation of latency-lytic switch by CHD4.

Authors:  Ashish Kumar; Yuanzhi Lyu; Yuichi Yanagihashi; Chanikarn Chantarasrivong; Vladimir Majerciak; Michelle Salemi; Kang-Hsin Wang; Tomoki Inagaki; Frank Chuang; Ryan R Davis; Clifford G Tepper; Kazushi Nakano; Chie Izumiya; Michiko Shimoda; Ken-Ichi Nakajima; Alexander Merleev; Zhi-Ming Zheng; Mel Campbell; Yoshihiro Izumiya
Journal:  Cell Rep       Date:  2022-05-10       Impact factor: 9.995

4.  Bromodomain Inhibitors Modulate FcγR-Mediated Mononuclear Phagocyte Activation and Chemotaxis.

Authors:  Gemma D Banham; Colin Y C Lee; John R Ferdinand; Rebeccah J Matthews; Chenzhi Jing; Nicholas Smithers; Rab K Prinjha; Menna R Clatworthy
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

5.  A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.

Authors:  Kunlong Zhang; Li Gao; Jianwei Wang; Xinran Chu; Zimu Zhang; Yongping Zhang; Fang Fang; Yanfang Tao; Xiaolu Li; Yuanyuan Tian; Zhiheng Li; Xu Sang; Li Ma; Lihui Lu; Yanling Chen; Juanjuan Yu; Ran Zhuo; Shuiyan Wu; Jian Pan; Shaoyan Hu
Journal:  Pathol Oncol Res       Date:  2022-06-27       Impact factor: 2.874

6.  BET family members Bdf1/2 modulate global transcription initiation and elongation in Saccharomyces cerevisiae.

Authors:  Rafal Donczew; Steven Hahn
Journal:  Elife       Date:  2021-06-17       Impact factor: 8.140

Review 7.  Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.

Authors:  Brandi N Reeves; Joan D Beckman
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 4.213

Review 8.  Pharmacological Modulation of BET Family in Sepsis.

Authors:  Nian Wang; Runliu Wu; Paul B Comish; Rui Kang; Daolin Tang
Journal:  Front Pharmacol       Date:  2021-03-11       Impact factor: 5.810

Review 9.  Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?

Authors:  Thanarat Salahong; Christian Schwartz; Rungroch Sungthong
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

10.  Genomic Identification, Evolution, and Expression Analysis of Bromodomain Genes Family in Buffalo.

Authors:  Junjun Zhang; Liangfeng Huang; Pengfei Zhang; Xingchen Huang; Weihan Yang; Runfeng Liu; Qinqiang Sun; Yangqing Lu; Ming Zhang; Qiang Fu
Journal:  Genes (Basel)       Date:  2022-01-01       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.